Clinical Trial Update: Durability and Tolerability of Infliximab in Pediatric Inflammatory Bowel Disease Patients: A 10 Year Single Center Experience

View source ↗

Summary

A 10-year single-center observational update evaluating the durability and tolerability of infliximab in pediatric inflammatory bowel disease patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Pediatric Inflammatory Bowel Disease | Status: UNKNOWN